Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

2.725 -0.055 (-1.98%)
Delayed Quote Updated: 9:56 AM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about C4 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Peak Bio, Inc. (NYSE: PKBO) shares jumped 49.1% to $7.08. 
Via Benzinga
C4 Therapeutics's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
News headline image
US Stocks Mixed On Black Friday; Dow Rises Over 100 Points ↗
U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 100 points on Friday. Equity markets will close early on Black Friday, the day after Thanksgiving. 
Via Benzinga
News headline image
C4 Therapeutics: Q3 Earnings Insights ↗
C4 Therapeutics (NASDAQ:CCCC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Recap: C4 Therapeutics Q2 Earnings ↗
  C4 Therapeutics (NASDAQ:CCCC) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday ↗
Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share. 
Via Benzinga
News headline image
Credit Suisse, Autodesk And Other Big Losers From Wednesday ↗
U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
News headline image
C4 Therapeutics: Q1 Earnings Insights ↗
C4 Therapeutics (NASDAQ:CCCC) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Where C4 Therapeutics Stands With Analysts ↗
Within the last quarter, C4 Therapeutics (NASDAQ:CCCC) has observed the following analyst ratings: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022 ↗
Upgrades 
Via Benzinga
News headline image
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗
Upgrades 
Via Benzinga
News headline image
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
Phase 1/2 Clinical Trial Will Study CFT1946 in BRAF-V600 Mutant Solid Cancers Including Lung, Colorectal and Melanoma; Trial Initiation Expected by Year End 2022 
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics's Return On Capital Employed Insights ↗
According to Benzinga Pro data, during Q2, C4 Therapeutics (NASDAQ:CCCC) posted sales of $13.83 million. Earnings were up 13.31%, but C4 Therapeutics still reported an overall loss of $27.41 million. 
Via Benzinga
News headline image
C4 Therapeutics's Return On Capital Employed Overview ↗
C4 Therapeutics (NASDAQ:CCCC) brought in sales totaling $7.65 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 101.94%, resulting in a loss of $31.62 million. 
Via Benzinga
News headline image
C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers ↗
C4 Therapeutics, Inc. (C4T) (NASDAQ: CCCC) has dosed the first patient in the Phase 1/2 clinical trial of its drug candidate CFT8634, for the treatment of SMARCB1-perturbed cancers, including synovial... 
Via Benzinga
News headline image
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday ↗
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday. 
Via Benzinga
News headline image
66 Biggest Movers From Yesterday ↗
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged... 
Via Benzinga
News headline image
31 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) climbed 64.9% to $9.86. Redbox recently reported CFO transition. SoundHound AI, Inc. (NASDAQ: SOUN) shares gained 30.5% to $8.48... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) shares increased by 331.5% to $10.4 during Tuesday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
BMO Capital Maintains Outperform Rating for C4 Therapeutics, Lowers Price Target To $20 ↗
BMO Capital has decided to maintain its Outperform rating of C4 Therapeutics (NASDAQ:CCCC) and lower its price target from $57.00 to $20.00. Shares of C4 Therapeutics are trading down 20.49% over the... 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More ↗
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
News headline image
Why C4 Therapeutics Stock Is Plunging Today ↗
C4 Therapeutics Inc (NASDAQ: CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongoing Phase 1/2 clinical... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.